Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Hepatitis C

Free Subscription 26.08.2019 1 BMC Gastroenterol 1 Dig Dis Sci 1 Eur J Gastroenterol Hepatol 1 Hepatology 2 J Gen Virol 2 J Hepatol 3 J Viral Hepat 2 PLoS One 1 Scand J Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

BMC Gastroenterol

1. MIDORIKAWA Y, Takayama T, Nakayama H, Higaki T, et al
   Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma.
   BMC Gastroenterol. 2019;19:147.
   PubMed     Text format     Abstract available
   
   

   
   Dig Dis Sci

2. FELD JJ, Krassenburg LAP
   What Comes First: Treatment of Viral Hepatitis or Liver Cancer?
   Dig Dis Sci. 2019 Mar 14. pii: 10.1007/s10620-019-05518.
   PubMed     Text format     Abstract available
   
   

   
   Eur J Gastroenterol Hepatol

3. DURCAN E, Hatemi I, Sonsuz A, Canbakan B, et al
   The effect of direct antiviral treatment on the depression, anxiety, fatigue and quality-of-life in chronic hepatitis C patients.
   Eur J Gastroenterol Hepatol. 2019 Aug 20. doi: 10.1097/MEG.0000000000001501.
   PubMed     Text format     Abstract available
   
   

   
   Hepatology

4. JOHIRA Y, Hatooka H, Mori N, Fukuhara T, et al
   Regression of idiopathic thrombocytopenic purpura in a patient with eradication of hepatitis C virus by direct-acting antivirals.
   Hepatology. 2019 Aug 20. doi: 10.1002/hep.30900.
   PubMed     Text format     Abstract available
   
   

   
   J Gen Virol

5. BEECH H
   Expression of concern: Hepatitis C virus activates interleukin-1beta via caspase-1-inflammasome complex.
   J Gen Virol. 2019 Aug 23. doi: 10.1099/jgv.0.001313.
   PubMed     Text format    
   
   
6. BEECH H
   Expression of concern: Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway.
   J Gen Virol. 2019 Aug 20. doi: 10.1099/jgv.0.001312.
   PubMed     Text format    
   
   

   
   J Hepatol

7. ROSSI C, Jeong D, Wong S, McKee G, et al
   Sustained Virologic Response from Interferon-based Hepatitis C regimes IS associated with Reduced risk of Extrahepatic Manifestations.
   J Hepatol. 2019 Aug 6. pii: S0168-8278(19)30462.
   PubMed     Text format     Abstract available
   
   
8. DEGASPERI E, Spinetti A, Lombardi A, Landonio S, et al
   Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure.
   J Hepatol. 2019 Aug 6. pii: S0168-8278(19)30461.
   PubMed     Text format     Abstract available
   
   

   
   J Viral Hepat

9. JACKA B, Roy E, Hoj S, Minoyan N, et al
   Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.
   J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13194.
   PubMed     Text format     Abstract available
   
   
10. ROSA-HEZODE I, Chousterman M, Costes L, Labourdette C, et al
    Cascade of care for migrants tested Hepatitis C antibodies positive in France through a systematic screening program: the PRECAVIR study.
    J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13192.
    PubMed     Text format     Abstract available
    
    
11. TSAI MC, Lin CY, Hung CH, Lu SN, et al
    Evolution of Renal function under directly acting antivirals treatment for chronic hepatitis C: A real world experience.
    J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13193.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

12. PUGA MAM, Bandeira LM, Pompilio MA, Rezende GR, et al
    Screening for HBV, HCV, HIV and syphilis infections among bacteriologically confirmed tuberculosis prisoners: An urgent action required.
    PLoS One. 2019;14:e0221265.
    PubMed     Text format     Abstract available
    
    
13. KWO PY, Puenpatom A, Zhang Z, Hui SL, et al
    Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.
    PLoS One. 2019;14:e0218759.
    PubMed     Text format     Abstract available
    
    

    
    Scand J Gastroenterol

14. KJELLIN M, Kileng H, Akaberi D, Palanisamy N, et al
    Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway.
    Scand J Gastroenterol. 2019 Aug 19:1-9. doi: 10.1080/00365521.2019.1652846.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: